Volcano Announces Limited Market Release of SyncVision™ Technology System
New system allows co-registration of angiography with intravascular imaging
SAN DIEGO, April 25, 2014
SAN DIEGO, April 25, 2014 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC),
a leading developer and manufacturer of precision guided therapy tools
designed to enhance the diagnosis and treatment of coronary and peripheral
vascular disease, today announced the commencement of its limited market
release of its FDA cleared and CE marked technology SyncVision™, with cases
being performed in the U.S. and Europe. SyncVision™ is currently installed in
multiple limited market release sites throughout U.S. and Europe.
Volcano's SyncVision™ Technology System is an on-line image processing
workstation for coronary catheterizations that allows the physician to
navigate simultaneously on an angiogram and on an IVUS image in a single
correlated view using co-registration of the Eagle Eye^® Platinum catheter
with x-ray angiography. SyncVision™ is designed to bring the detailed vessel,
lumen and wall structure from angiography and the spatial localization of
Volcano's intravascular ultrasound images within the coronary tree together in
a co-registered view to facilitate more informed treatment decisions and more
efficient, enhanced workflow performance.
"SyncVision™ is an important advancement in clinical IVUS imaging. It allows
us to correlate significant IVUS findings with the corresponding spots on the
angiogram. This addresses a challenging aspect of current practice in that it
can be difficult to identify the precise spot needing treatment in translating
the IVUS findings to the angiogram," commented Steven Goldberg, M.D.,
Director, Cardiac Catheterization Laboratory and Clinical Associate Professor
of Medicine at University of Washington Medical Center. "It also allows for
simple and precise length measurements to help inform stent selection.
Co-registration of different imaging modalities is currently the wave in
interventional cardiology, and I think this is one of the most useful and user
friendly co-registration formats I have seen. I believe that this truly
represents the next generation in IVUS imaging."
"The co-registration with angiography makes of IVUS an entirely new
instrument. As a regular IVUS user, I was impressed to see how it helps in
making decisions based on intracoronary imaging," commented Javier Escaned,
M.D., Consultant Interventional Cardiologist, Hospital Clinico San Carlos.
"In addition, the angiographic tools incorporated in SyncVision™ are extremely
helpful during coronary interventions. Image stabilization and digital
enhancement based not only on cine but also on images under fluoroscopy is a
great complement of IVUS in performing accurate stent optimization without
geometric mismatch. My impression is that with this system we move into an
entirely new era of integration of IVUS and angiography in clinical
"We are looking forward to sharing the SyncVision™ technology with a global
audience next month at the EuroPCR meeting in Paris," said Joe Burnett,
Executive Vice President. "We will showcase the technology with working
systems at our booth and in the training village, as well as with expert panel
discussions and live case presentations."
"We are thrilled about the benefits and precision that the use of SyncVision™
enables in concert with our Eagle Eye Platinum Catheter and the Angio +™
applications. SyncVision™ will change the game in that it empowers easier and
better interpretations of both IVUS and angio technologies that are designed
to encourage quicker and confident decisions," said Scott Huennekens,
President and Chief Executive Officer. "SyncVision™ Technology System
demonstrates innovation in design and a commitment to our continued
investments in Volcano solutions for our customers. This system further
bolsters our portfolio of recent innovative releases with the iFR^® modality,
CORE™ Precision Guided System, and CORE™ Control Pad—all of which work to help
improve patient outcomes and customer productivity."
SyncVision™ is expected to be in full market release later in 2014.
Additional product information is available at www.volcanocorp.com.
Volcano Corporationis revolutionizing the medical device industry with a
broad suite of technologies that make imaging and therapy simpler, more
informative and less invasive. Our products empower physicians around the
world with a new generation of analytical tools that deliver more meaningful
information - using sound and light as the guiding elements. Founded in
cardiovascular care and expanding into other specialties, Volcano is changing
the assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.
This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this release that are not historical facts may be considered "forward-looking
statements," including statements regarding the potential benefits and
effectiveness of the products and technologies described above, further market
development and expansion and anticipated market impact. Forward-looking
statements are based on management's current expectations and are subject to
risks and uncertainties which may cause Volcano's results to differ materially
and adversely from the statements contained herein. Some of the potential
risks and uncertainties that could cause actual results to differ include the
pace and extent of market adoption of the company's products and technologies;
unexpected clinical trial results, including unexpected new clinical data and
unexpected additional analysis of existing clinical data; unexpected
regulatory actions or delays or government regulation generally; the company's
ability to obtain or maintain patent or other proprietary intellectual
property protection; competition in general; government, industry and general
public pricing pressures; unexpected manufacturing issues; growth strategies;
timing and achievement of product development milestones; outcome of ongoing
litigation; the impact and benefits of market development; product
introductions; unexpected new data, safety and technical issues; market
conditions; and other risks inherent to medical device development and
commercialization. These and additional risks and uncertainties are more fully
described in Volcano's filings made with theSecurities and Exchange
Commission, including our recent report on Form 10-K. Undue reliance should
not be placed on forward-looking statements which speak only as of the date
they are made. Volcano undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated events.
SOURCE Volcano Corporation
Contact: Media, Tom Osypian, Volcano Corporation, email@example.com,
858-720-4086, or Investor Relations, Neal Rosen, Volcano Corporation,
Press spacebar to pause and continue. Press esc to stop.